Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples